EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Recent Advances in Combined Medical and Surgical Therapy for Resectable NSCLC

Adithya Balasubramanian iD, James Geng, Catherine Williams, Kanishka Rangamuwa iD, Thomas John

Respirology · 2026-05 · 31 (5) · 443-458

DOI: 10.1002/resp.70238 ↗

At a glance

Übersichtsarbeit in Respirology, published online on 2026-03-18. Written by Adithya Balasubramanian and 4 co-authors. Institution: Department of Medical Oncology, The Peter MacCallum Cancer Centre, Melbourne, Australia. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. 119 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Non‐small cell lung cancer (NSCLC) remains the leading cause of cancer related mortality. Historically, even among patients with resectable disease, most would not survive 5 years after curative intent surgery. However, outcomes continue to improve through parallel advances in surgery and systemic therapy, the latter aiming to eradicate micrometastatic disease that underpins NSCLC relapse. The advent of precision oncology has transformed the management of oncogene‐addicted NSCLC, with tyrosine kinase inhibitors (TKIs) demonstrating significant survival improvements in advanced disease. These agents are now demonstrating their efficacy in molecularly defined subsets of resectable NSCLC—specifically EGFR and ALK mutant tumours—whereby adjuvant TKI therapy significantly reduces recurrence compared with historical platinum‐based chemotherapy. In parallel, the immunotherapeutic era has ushered in a new paradigm of curative intent therapy, with immune checkpoint inhibitors (ICIs) improving pathological responses and survival in the perioperative setting. Together, these developments continue to redefine personalised, optimal treatment algorithms for resectable NSCLC. This review outlines the biological rationale and clinical evidence for utilising systemic therapy in the perioperative management of NSCLC. We discuss emerging strategies‐ such as biomarker‐driven, risk‐adapted and multimodal approaches‐ designed to further mitigate the risk of potentially fatal relapse whilst avoiding overtreatment for patients with resectable disease.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansCombined Modality TherapyProtein Kinase InhibitorsImmune Checkpoint InhibitorsImmunotherapyPneumonectomy

Author keywords

adjuvantchemotherapyimmunotherapyneoadjuvantnon‐small cell lung cancerperioperativetargeted therapy

Substances

Protein Kinase InhibitorsImmune Checkpoint Inhibitors

Authors and institutions

  • Department of Medical Oncology, The Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Department of Medical Oncology, Monash Health, Melbourne, Australia.
  • Personalised Oncology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
  • Department of Medical Biology, The University of Melbourne, Parkville, Australia.
  • Department of Respiratory Medicine, Royal Melbourne Hospital, Parkville, Australia.
  • Department of Respiratory Medicine, Northern Health, Epping, Australia.

ORCID profiles: Adithya Balasubramanian, Kanishka Rangamuwa

Cite

APA

Balasubramanian, A., Geng, J., Williams, C., Rangamuwa, K., & John, T. (2026). Recent Advances in Combined Medical and Surgical Therapy for Resectable NSCLC. Respirology, 31(5), 443-458. https://doi.org/10.1002/resp.70238

Vancouver

Balasubramanian A, Geng J, Williams C, Rangamuwa K, John T. Recent Advances in Combined Medical and Surgical Therapy for Resectable NSCLC. Respirology. 2026;31(5):443-458. doi:10.1002/resp.70238

BibTeX
@article{Balasubramanian2026,
  author = {Balasubramanian, Adithya and Geng, James and Williams, Catherine and Rangamuwa, Kanishka and John, Thomas},
  title = {Recent Advances in Combined Medical and Surgical Therapy for Resectable NSCLC},
  journal = {Respirology},
  year = {2026},
  volume = {31},
  number = {5},
  pages = {443--458},
  doi = {10.1002/resp.70238}
}
Start for free →